Immunic (Vital Therapies) Priced, Nasdaq: IMUX
Developing bio-artificial liver cells for the treatment of acute liver failure.
Industry: Health Care
First Day Return: 0.0%
IMUX
Developing bio-artificial liver cells for the treatment of acute liver failure.
| IPO Data | |
|---|---|
| IPO Date | 04/16/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $54 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | San Diego, CA, United States |
| Founded | 2003 |
| Employees at IPO | 70 |
| Website www.vitaltherapies.com | |
IPO News for Immunic (Vital Therapies)
Immunic (Vital Therapies) (IMUX) Performance
